Sana Biotechnology, Inc.
Sangamo Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered cell therapies using proprietary ex vivo and in vivo cell engineering platforms. The company's website is www.sangamo.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Sana Biotechnology, Inc. does
In the company’s own words
Sangamo Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered cell therapies using proprietary ex vivo and in vivo cell engineering platforms. The company's website is www.sangamo.com.
Sangamo operates two distinct therapeutic platforms designed to address significant unmet medical needs across multiple disease areas. The ex vivo platform leverages the company's hypoimmune platform technology, referred to as HIP technology, which engineers allogeneic cells to evade immune rejection without requiring immunosuppression. The in vivo platform utilizes fusogen-based delivery technology to enable cell-specific genetic modification directly within patients' bodies.
The company's lead program, SC451, is an induced pluripotent stem cell-derived hypoimmune pancreatic islet cell therapy in development for type 1 diabetes. Sangamo's clinical validation includes positive results from a first-in-human investigator-sponsored study of UP421, a HIP-modified allogeneic primary islet cell therapy, which demonstrated survival and function of transplanted pancreatic beta cells for twelve months without immunosuppression. The company's second major program, SG293, is an in vivo CAR T cell candidate utilizing the fusogen platform for treatment of B cell malignancies and B cell-mediated autoimmune diseases.
Sangamo has built internal capabilities across stem cell and disease biology, immunology, genome modification, and gene delivery. The company maintains worldwide rights to its product candidates and has established partnerships with contract development and manufacturing organizations to support manufacturing scale-up. The company is a smaller reporting company and non-accelerated filer with the Securities and Exchange Commission.
As a clinical-stage company with no approved products for commercial sale, Sangamo has incurred significant losses since inception and expects to continue operating at a loss. The company requires additional funding to finance ongoing operations and clinical development programs. The company faces substantial doubt regarding its ability to continue as a going concern and is dependent on raising capital to advance its pipeline through clinical trials and regulatory approval processes.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 1770121
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Sana Biotechnology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Sana Biotechnology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Sana Biotechnology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Sana Biotechnology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Sana Biotechnology, Inc.'s last four quarterly filings that the numbers alone won't show?”